Loading...
OTCM
DVYSF
, Last price  
USD
Name

Devyser Diagnostics publ AB

Chart & Performance

D1W1MN
OTCM:DVYSF chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
41.72%
Rev. gr., 5y
30.70%
Revenues
251m
+15.49%
48,148,00064,303,00065,689,00093,481,000126,613,000169,300,000216,900,000250,500,000
Net income
-8m
L-86.34%
519,0007,009,000-10,911,000-20,727,000-45,953,000-53,600,000-61,500,000-8,400,000
CFO
8m
P
6,020,00014,631,000627,000-16,482,000-40,501,000-69,700,000-46,800,0008,199,999

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Headquartered in Hägersten, Sweden, and established in 2004, Devyser Diagnostics AB (publ) specializes in the development, manufacturing, and global sale of advanced diagnostic kits and solutions for DNA testing. The company's innovative products are crucial for genetic analysis in key medical areas, including hereditary diseases, oncology, and post-transplantation monitoring. Devyser offers a broad array of diagnostic tools, covering applications such as post-transplant management, thalassemia screening, and the detection of various cancers like breast, colorectal, and ovarian. Their portfolio also extends to non-invasive fetal RHD screening, diagnostics for inherited conditions, cystic fibrosis, cardiovascular issues, male infertility, and rapid aneuploidy analysis, complemented by essential accessories. These solutions are utilized for diverse purposes, from diagnosing genetic disorders and guiding targeted cancer treatments to ensuring thorough follow-up care for transplant patients. Furthermore, Devyser provides specialized software programs, including Amplicon Suite and Advyser, which facilitate the processing, analysis, and interpretation of test results, enabling efficient marker screening and patient sample tracking. The company's operations span Sweden, the broader European market, the Middle East, Africa, North and South America, and Asia.
IPO date
Employees
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT